U.S. markets closed
  • S&P Futures

    4,385.75
    -8.00 (-0.18%)
     
  • Dow Futures

    34,819.00
    -15.00 (-0.04%)
     
  • Nasdaq Futures

    14,961.00
    -50.50 (-0.34%)
     
  • Russell 2000 Futures

    2,222.70
    +2.00 (+0.09%)
     
  • Crude Oil

    72.70
    +0.31 (+0.43%)
     
  • Gold

    1,815.20
    +15.50 (+0.86%)
     
  • Silver

    25.25
    +0.38 (+1.52%)
     
  • EUR/USD

    1.1858
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3926
    +0.0017 (+0.12%)
     
  • USD/JPY

    109.8030
    -0.1070 (-0.10%)
     
  • BTC-USD

    39,884.16
    -40.02 (-0.10%)
     
  • CMC Crypto 200

    933.70
    +3.77 (+0.41%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,687.28
    +105.62 (+0.38%)
     

AstraZeneca's Anifrolumab Shows Benefit In Skin, Joint Diseases In Systemic Lupus Erythematosus Patients

·1 min read
  • AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with moderate to severe systemic lupus erythematosus (SLE).

  • Data were presented at the annual European Congress of Rheumatology (EULAR 2021).

  • Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body.

  • The analysis showed anifrolumab was consistently associated with improvements in skin rash and arthritis across three different disease measures, compared to placebo, in SLE patients.

  • For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 was 13.5% SLE disease activity index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG), and 15.6% modified Cutaneous Lupus Erythematosus severity index (mCLASI).

  • For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG, and 12.6% joint response.

  • The most frequently reported adverse events for anifrolumab in the TULIP-1 and TULIP-2 trials were upper respiratory tract infection, bronchitis, infusion-related reactions, and herpes zoster.

  • AstraZeneca’s application for anifrolumab in SLE is under review by regulatory authorities in the U.S., E.U., and Japan, with decisions anticipated in the second half of 2021.

  • Price Action: AZN shares are down 0.5% at $55.98 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.